查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1790435

美国抗毒素市场规模、份额和趋势分析报告：按类型、作用机制、最终用途和细分市场预测，2025 年至 2030 年

U.S. Anti-Venom Market Size, Share & Trends Analysis Report By Species (Snake, Scorpion, Spider), By Type (Polyvalent, Monovalent), By Mode of Action (Cytotoxic, Neurotoxic), By End Use, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10个工作天内

价格

美国抗蛇毒血清市场概况

预计 2024 年美国抗蛇毒血清市场规模为 4.245 亿美元，到 2030 年将达到 6.7 亿美元，2025 年至 2030 年期间的复合年增长率为 8.0%。由于毒咬和毒蜇事件（尤其是蛇和昆虫的毒咬和蜇刺事件）的发生率不断上升，市场正在扩大。

都市化、森林砍伐和气候变迁正在影响这些动物的栖息地，并加剧了有毒物种与人类之间的互动。这些趋势推动了美国毒液中毒治疗产业的发展，增加了对有效毒液中毒治疗的需求，以减少毒液中毒造成的死亡和长期健康併发症。

生物技术的进步对市场成长贡献巨大。单株抗体抗蛇毒药物和重组DNA技术等进展，正在推动更有效、更安全的标靶治疗疗法的开发。这些技术进步正在改善治疗效果，降低生产成本，使抗蛇毒血清更容易取得。製药公司和研究机构（尤其是在美国）持续不断的研发投入，正在推动创新，并促进针对特定蛇毒类型的先进抗蛇毒血清的推出。

美国市场受惠于其健全的医疗保健体系，能够在紧急情况下快速获得抗蛇毒治疗。户外休閒活动的日益普及以及市场向野生动物栖息地的扩张，增加了接触有毒生物的可能性，从而推动了市场需求。此外，主要产业参与企业的参与以及政府对医药创新的持续支持，也增强了市场的成长前景。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国抗蛇毒血清市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 美国抗蛇毒血清市场分析工具
    • 产业分析—波特五力分析
    • PESTEL分析
  • 美国抗毒素市场：渠道分析

第四章：美国抗毒素市场类型、估价与趋势分析

  • 物种细分仪表板
  • 美国抗蛇毒市场：物种变异分析
  • 美国抗毒素市场规模及趋势分析（按类型，2018-2030）
  • 蛇
    • 普通眼镜蛇
    • 普通板条箱
    • 拉塞尔·维珀
    • 其他的
  • 蝎
  • 蜘蛛
  • 其他的

第五章：美国抗毒素市场类型、估价与趋势分析

  • 类型细分仪表板
  • 美国抗毒素市场：类型变化分析
  • 美国抗毒素市场规模及趋势分析（2018-2030）
  • 多效价
  • 单一值

第六章：美国抗毒素市场的作用机制、估价与趋势分析

  • 作用机制细分仪表板
  • 美国抗毒素市场：作用机制变异分析
  • 美国抗毒素市场规模及趋势分析（依作用机制，2018-2030）
  • 细胞毒性
  • 神经毒性
  • 血液毒性
  • 心臟毒性
  • 肌肉毒性
  • 其他的

第七章：美国抗毒素市场最终用途、预测与趋势分析

  • 最终用途细分仪表板
  • 美国抗毒素市场：最终用途差异分析
  • 2018-2030年美国抗毒素市场规模及最终用途趋势分析
  • 医院
  • 诊所
  • 门诊手术中心

第八章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 2024年主要企业热图分析
  • 公司简介
    • Boehringer Ingelheim
    • CSL Limited
    • Merck & Co., Inc.
    • Pfizer, Inc.
Product Code: GVR-4-68040-680-8

U.S. Anti-Venom Market Summary

The U.S. anti-venom market size was estimated at USD 424.5 million in 2024 and is projected to reach USD 670.0 million by 2030, growing at a CAGR of 8.0% from 2025 to 2030. The market is expanding due to the rising incidence of venomous bites and stings, especially from snakes and insects.

Increased human interaction with venomous species is fueled by urbanization, deforestation, and climate change, which have impacted the habitats of these animals and brought them closer to populated areas. This trend has heightened the need for effective anti-venom treatments to reduce fatalities and long-term health complications associated with envenomation, driving the U.S. anti-venom industry.

Advancements in biotechnology significantly contribute to market growth. Innovations such as monoclonal antibody-based anti-venoms and recombinant DNA technologies have resulted in the development of more potent, safer, and targeted therapies. These improvements enhance treatment outcomes and help reduce production costs, making anti-venoms more accessible. The continuous research and development efforts by pharmaceutical companies and research institutions, particularly in the U.S., foster innovation and the introduction of advanced anti-venom products tailored to specific venom types.

The U.S. market benefits from a robust healthcare system that facilitates rapid access to anti-venom treatments in emergency settings. The prevalence of outdoor recreational activities and expanding urban development into wildlife habitats increases the likelihood of encounters with venomous species, thereby driving market demand. Moreover, the presence of key industry players and ongoing government support for pharmaceutical innovation strengthen the market's growth prospects.

U.S. Anti-Venom Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. anti-venom market report based on species, type, mode of action, and end use.

  • Species Outlook (Revenue, USD Million, 2018 - 2030)
  • Snake
    • Common Cobra
    • Common Krait
    • Russell Viper
    • Others
  • Scorpion
  • Spider
  • Other
  • Type Outlook (Revenue, USD Million, 2018 - 2030)
  • Polyvalent
  • Monovalent
  • Mode of Action Outlook (Revenue, USD Million, 2018 - 2030)
  • Cytotoxic
  • Neurotoxic
  • Hemotoxic
  • Cardiotoxic
  • Myotoxic
  • Others
  • End Use Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Species
    • 1.2.2. Type
    • 1.2.3. Mode of action
    • 1.2.4. End use
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Species outlook
    • 2.2.2. Type outlook
    • 2.2.3. Mode of action outlook
    • 2.2.4. End use outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Anti-Venom Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Anti-Venom Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. U.S. Anti-Venom Market: Pipeline Analysis

Chapter 4. U.S. Anti-Venom Market: Species Estimates & Trend Analysis

  • 4.1. Species Segment Dashboard
  • 4.2. U.S. Anti-Venom Market: Species Movement Analysis
  • 4.3. U.S. Anti-Venom Market Size & Trend Analysis, by Species, 2018 to 2030 (USD Million)
  • 4.4. Snake
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Common Cobra
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Common Krait
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Russell Viper
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Others
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Scorpion
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Spider
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Other
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Anti-Venom Market: Type Estimates & Trend Analysis

  • 5.1. Type Segment Dashboard
  • 5.2. U.S. Anti-Venom Market: Type Movement Analysis
  • 5.3. U.S. Anti-Venom Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 5.4. Polyvalent
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Monovalent
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Anti-Venom Market: Mode of Action Estimates & Trend Analysis

  • 6.1. Mode of Action Segment Dashboard
  • 6.2. U.S. Anti-Venom Market: Mode of Action Movement Analysis
  • 6.3. U.S. Anti-Venom Market Size & Trend Analysis, by Mode of Action, 2018 to 2030 (USD Million)
  • 6.4. Cytotoxic
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Neurotoxic
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Hemotoxic
    • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Cardiotoxic
    • 6.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Myotoxic
    • 6.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. Others
    • 6.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Anti-Venom Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Segment Dashboard
  • 7.2. U.S. Anti-Venom Market: End Use Movement Analysis
  • 7.3. U.S. Anti-Venom Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 7.4. Hospitals
    • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Clinics
    • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Ambulatory Surgical Centers
    • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company heat map analysis, 2024
  • 8.4. Company Profiles
    • 8.4.1. Boehringer Ingelheim
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. CSL Limited
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Merck & Co., Inc.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Pfizer, Inc.
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. anti-venom market, by species, 2018 - 2030 (USD Million)
  • Table 3 U.S. anti-venom market, by snake 2018 - 2030 (USD Million)
  • Table 4 U.S. anti-venom market, by type 2018 - 2030 (USD Million)
  • Table 5 U.S. anti-venom market, by mode of action 2018 - 2030 (USD Million)
  • Table 6 U.S. anti-venom market, by end use 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. anti-venom market: market outlook
  • Fig. 10 U.S. anti-venom competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. anti-venom market driver impact
  • Fig. 16 U.S. anti-venom market restraint impact
  • Fig. 17 U.S. anti-venom market strategic initiatives analysis
  • Fig. 18 U.S. anti-venom market: Species movement analysis
  • Fig. 19 U.S. anti-venom market: Species outlook and key takeaways
  • Fig. 20 Snake market estimates and forecasts, 2018 - 2030
  • Fig. 21 Common cobra market estimates and forecasts, 2018 - 2030
  • Fig. 22 Common krait market estimates and forecasts, 2018 - 2030
  • Fig. 23 Russell viper market estimates and forecasts, 2018 - 2030
  • Fig. 24 Others market estimates and forecasts, 2018 - 2030
  • Fig. 25 Scorpion market estimates and forecasts, 2018 - 2030
  • Fig. 26 Spider market estimates and forecasts, 2018 - 2030
  • Fig. 27 Other market estimates and forecasts, 2018 - 2030
  • Fig. 28 U.S. anti-venom market: Type movement analysis
  • Fig. 29 U.S. anti-venom market: Type outlook and key takeaways
  • Fig. 30 Polyvalent market estimates and forecasts, 2018 - 2030
  • Fig. 31 Monovalent market estimates and forecasts, 2018 - 2030
  • Fig. 32 U.S. anti-venom market: Mode of Action movement analysis
  • Fig. 33 U.S. anti-venom market: Mode of Action outlook and key takeaways
  • Fig. 34 Cytotoxic market estimates and forecasts, 2018 - 2030
  • Fig. 35 Neurotoxic market estimates and forecasts, 2018 - 2030
  • Fig. 36 Hemotoxic market estimates and forecasts, 2018 - 2030
  • Fig. 37 Cardiotoxic market estimates and forecasts, 2018 - 2030
  • Fig. 38 Myotoxic market estimates and forecasts, 2018 - 2030
  • Fig. 39 Others market estimates and forecasts, 2018 - 2030
  • Fig. 40 U.S. anti-venom market: End Use movement analysis
  • Fig. 41 U.S. anti-venom market: End Use outlook and key takeaways
  • Fig. 42 Hospitals market estimates and forecasts, 2018 - 2030
  • Fig. 43 Clinics market estimates and forecasts, 2018 - 2030
  • Fig. 44 Ambulatory surgical centers market estimates and forecasts, 2018 - 2030